FindTrial
Sign In

Efficacy of statins in preventing decline in heart function in patients with permanent pacemaker

Efficacy of statins to reduce the incidence of pacemaker induced cardiomyopathy – An open label randomized controlled trial - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/076660
Enrollment
202
Registered
2024-11-12
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I442- Atrioventricular block, complete

Interventions

Intervention1: Administration of Atorvastatin 40 mg/day: Atorvastatin 40 mg per day will be given orally for 1 year to the patients (with permanent pacemaker) in study group along with standard medica

Sponsors

Jawaharlal Institute of Postgraduate Medical Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Underwent pacemaker implantation within three days 2.Anticipated ventricular pacing requirement more than 40%

Exclusion criteria

Exclusion criteria: 1.Patients with LVEF 2.Patients who are already on statins or have an indication for statins

Design outcomes

Primary

MeasureTime frame
Development of pacemaker induced cardiomyopathyTimepoint: 1 year—

Secondary

MeasureTime frame
Incidence of elevated NT-proBNP levels at six months in both the statin and control groupTimepoint: 6 months—

Countries

India

Contacts

Public ContactRohit Varma

Jawaharlal Institute of Postgraduate Medical Education and Research

rajajs@gmail.com9442242648

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026